|
1
|
Jemal A, Siegel R, Ward E, et al: Cancer
statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cannistra SA: Cancer of the ovary. N Engl
J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heintz AP, Odicino F, Maisonneuve P, et
al: Carcinoma of the ovary. FIGO 26th annual report on the results
of treatment in gynecological cancer. Int J Gynaecol Obstet.
95(Suppl 1): 161–192. 2006. View Article : Google Scholar
|
|
4
|
Wang M, He Y, Shi L and Shi C:
Multivariate analysis by Cox proportional hazard model on prognosis
of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol.
32:171–177. 2011.PubMed/NCBI
|
|
5
|
Djuranovic S, Nahvi A and Green R: A
parsimonious model for gene regulation by miRNAs. Science.
331:550–553. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kasinski AL and Slack FJ: Epigenetics and
genetics. MicroRNAs en route to the clinic: progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iorio MV, Visone R, Di Leva G, et al:
MicroRNA signatures in human ovarian cancer. Cancer Res.
67:8699–8707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iorio MV and Croce CM: MicroRNAs in
cancer: small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin J, Huang S, Wu S, et al: MicroRNA-423
promotes cell growth and regulates G (1)/S transition by targeting
p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis.
32:1641–1647. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jovanovic M and Hengartner MO: miRNAs and
apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stevanato L and Sinden JD: The effects of
microRNAs on human neural stem cell differentiation in two- and
three-dimensional cultures. Stem Cell Res Ther. 5:492014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ghosh G, Subramanian IV, Adhikari N, et
al: Hypoxia-induced microRNA-424 expression in human endothelial
cells regulates HIF-alpha isoforms and promotes angiogenesis. J
Clin Invest. 120:4141–4154. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schommer C, Palatnik JF, Aggarwal P, et
al: Control of jasmonate biosynthesis and senescence by miR319
targets. PLoS Biol. 6:e2302008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iorio MV and Croce CM: Causes and
consequences of microRNA dysregulation. Cancer J. 18:215–222. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang W, Jiang Y, Mu X, Xu L, Cheng W and
Wang X: MiR-135a functions as a tumor suppressor in epithelial
ovarian cancer and regulates HOXA10 expression. Cell Signal.
26:1420–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang H, Wang Q, Zhao Q and Di W: MiR-124
inhibits the migration and invasion of ovarian cancer cells by
targeting SphK1. J Ovarian Res. 6:842013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhattacharya R, Nicoloso M, Arvizo R, et
al: MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer.
Cancer Res. 69:9090–9095. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hong F, Li Y, Xu Y and Zhu L: Prognostic
significance of serum microRNA-221 expression in human epithelial
ovarian cancer. J Int Med Res. 41:64–71. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Corney DC, Hwang CI, Matoso A, et al:
Frequent downregulation of miR-34 family in human ovarian cancers.
Clin Cancer Res. 16:1119–1128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang W, Wang Q, Yu M, Wu N and Wang H:
MicroRNA-145 function as a cell growth repressor by directly
targeting c-Myc in human ovarian cancer. Technol Cancer Res Treat.
13:161–168. 2014.
|
|
23
|
Guo J, Xia B, Meng F and Lou G: miR-137
suppresses cell growth in ovarian cancer by targeting AEG-1.
Biochem Biophys Res Commun. 441:357–363. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li P, Ma L, Zhang Y, Ji F and Jin F:
MicroRNA-137 down-regulates KIT and inhibits small cell lung cancer
cell proliferation. Biomed Pharmacother. 68:7–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kozaki K, Imoto I, Mogi S, Omura K and
Inazawa J: Exploration of tumor-suppressive microRNAs silenced by
DNA hypermethylation in oral cancer. Cancer Res. 68:2094–2105.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ando T, Yoshida T, Enomoto S, et al: DNA
methylation of microRNA genes in gastric mucosae of gastric cancer
patients: its possible involvement in the formation of epigenetic
field defect. Int J Cancer. 124:2367–2374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun Y, Zhao X, Zhou Y and Hu Y: miR-124,
miR-137 and miR-340 regulate colorectal cancer growth via
inhibition of the Warburg effect. Oncol Rep. 28:1346–1352.
2012.PubMed/NCBI
|
|
28
|
Chen L, Wang X, Wang H, et al: miR-137 is
frequently down-regulated in glioblastoma and is a negative
regulator of Cox-2. Eur J Cancer. 48:3104–3111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao Y, Li Y, Lou G, et al: MiR-137
targets estrogen-related receptor alpha and impairs the
proliferative and migratory capacity of breast cancer cells. PLoS
One. 7:e391022012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mehta SP, Jose P, Mirza A, Pritchard SA,
Hayden JD and Grabsch HI: Comparison of the prognostic value of the
6th and 7th editions of the Union for International Cancer Control
TNM staging system in patients with lower esophageal cancer
undergoing neoadjuvant chemotherapy followed by surgery. Dis
Esophagus. 26:182–188. 2013. View Article : Google Scholar
|
|
31
|
Wu B, Li S, Sheng L, et al: Metformin
inhibits the development and metastasis of ovarian cancer. Oncol
Rep. 28:903–908. 2012.PubMed/NCBI
|
|
32
|
Chen Q, Chen X, Zhang M, Fan Q, Luo S and
Cao X: miR-137 is frequently down-regulated in gastric cancer and
is a negative regulator of Cdc42. Dig Dis Sci. 56:2009–2016. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu LL, Lu SX, Li M, et al:
FoxD3-regulated microRNA-137 suppresses tumour growth and
metastasis in human hepatocellular carcinoma by targeting AKT2.
Oncotarget. 5:5113–5124. 2014.PubMed/NCBI
|
|
34
|
Bi Y, Han Y, Bi H, Gao F and Wang X:
miR-137 impairs the proliferative and migratory capacity of human
non-small cell lung cancer cells by targeting paxillin. Hum Cell.
27:95–102. 2014. View Article : Google Scholar
|
|
35
|
Hainaut P and Plymoth A: Targeting the
hallmarks of cancer: towards a rational approach to next-generation
cancer therapy. Curr Opin Oncol. 25:50–51. 2013. View Article : Google Scholar
|
|
36
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Silber J, Lim DA, Petritsch C, et al:
miR-124 and miR-137 inhibit proliferation of glioblastoma
multiforme cells and induce differentiation of brain tumor stem
cells. BMC Med. 6:142008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu X, Li Y, Shen H, et al: miR-137
inhibits the proliferation of lung cancer cells by targeting Cdc42
and Cdk6. FEBS Lett. 587:73–81. 2013. View Article : Google Scholar
|
|
39
|
Bier A, Giladi N, Kronfeld N, et al:
MicroRNA-137 is down-regulated in glioblastoma and inhibits the
stemness of glioma stem cells by targeting RTVP-1. Oncotarget.
4:665–676. 2013.PubMed/NCBI
|
|
40
|
Deng Y, Deng H, Bi F, et al: MicroRNA-137
targets carboxyl-terminal binding protein 1 in melanoma cell lines.
Int J Biol Sci. 7:133–137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao Y, Li Y, Lou G, et al: MiR-137
targets estrogen-related receptor alpha and impairs the
proliferative and migratory capacity of breast cancer cells. PLoS
One. 7:e391022012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu M, Lang N, Qiu M, et al: miR-137
targets Cdc42 expression, induces cell cycle G1 arrest and inhibits
invasion in colorectal cancer cells. Int J Cancer. 128:1269–1279.
2011. View Article : Google Scholar
|
|
43
|
Luo C, Tetteh PW, Merz PR, et al: miR-137
inhibits the invasion of melanoma cells through downregulation of
multiple oncogenic target genes. J Invest Dermatol. 133:768–775.
2013. View Article : Google Scholar
|
